Considerations for Antiplatelet Management of Carotid Stenting in the Setting of Mechanical Thrombectomy: A Delphi Consensus Statement.
Journal
AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
01
06
2020
accepted:
17
07
2020
pubmed:
31
10
2020
medline:
9
3
2021
entrez:
30
10
2020
Statut:
ppublish
Résumé
There are only few data and lack of consensus regarding antiplatelet management for carotid stent placement in the setting of endovascular stroke treatment. We aimed to develop a consensus-based algorithm for antiplatelet management in acute ischemic stroke patients undergoing endovascular treatment and simultaneous emergent carotid stent placement. We performed a literature search and a modified Delphi approach used Web-based questionnaires that were sent in several iterations to an international multidisciplinary panel of 19 neurointerventionalists from 7 countries. The first round included open-ended questions and formed the basis for subsequent rounds, in which closed-ended questions were used. Participants continuously received feedback on the results from previous rounds. Consensus was defined as agreement of ≥70% for binary questions and agreement of ≥50% for questions with >2 answer options. The results of the Delphi process were then summarized in a draft manuscript that was circulated among the panel members for feedback. A total of 5 Delphi rounds were performed. Panel members preferred a single intravenous aspirin bolus or, in jurisdictions in which intravenous aspirin is not available, a glycoprotein IIb/IIIa receptor inhibitor as intraprocedural antiplatelet regimen and a combination therapy of oral aspirin and a P2Y12 inhibitor in the postprocedural period. There was no consensus on the role of platelet function testing in the postprocedural period. More and better data on antiplatelet management for carotid stent placement in the setting of endovascular treatment are urgently needed. Panel members preferred intravenous aspirin or, alternatively, a glycoprotein IIb/IIIa receptor inhibitor as an intraprocedural antiplatelet agent, followed by a dual oral regimen of aspirin and a P2Y12 inhibitor in the postprocedural period.
Sections du résumé
BACKGROUND AND PURPOSE
There are only few data and lack of consensus regarding antiplatelet management for carotid stent placement in the setting of endovascular stroke treatment. We aimed to develop a consensus-based algorithm for antiplatelet management in acute ischemic stroke patients undergoing endovascular treatment and simultaneous emergent carotid stent placement.
MATERIALS AND METHODS
We performed a literature search and a modified Delphi approach used Web-based questionnaires that were sent in several iterations to an international multidisciplinary panel of 19 neurointerventionalists from 7 countries. The first round included open-ended questions and formed the basis for subsequent rounds, in which closed-ended questions were used. Participants continuously received feedback on the results from previous rounds. Consensus was defined as agreement of ≥70% for binary questions and agreement of ≥50% for questions with >2 answer options. The results of the Delphi process were then summarized in a draft manuscript that was circulated among the panel members for feedback.
RESULTS
A total of 5 Delphi rounds were performed. Panel members preferred a single intravenous aspirin bolus or, in jurisdictions in which intravenous aspirin is not available, a glycoprotein IIb/IIIa receptor inhibitor as intraprocedural antiplatelet regimen and a combination therapy of oral aspirin and a P2Y12 inhibitor in the postprocedural period. There was no consensus on the role of platelet function testing in the postprocedural period.
CONCLUSIONS
More and better data on antiplatelet management for carotid stent placement in the setting of endovascular treatment are urgently needed. Panel members preferred intravenous aspirin or, alternatively, a glycoprotein IIb/IIIa receptor inhibitor as an intraprocedural antiplatelet agent, followed by a dual oral regimen of aspirin and a P2Y12 inhibitor in the postprocedural period.
Identifiants
pubmed: 33122218
pii: ajnr.A6888
doi: 10.3174/ajnr.A6888
pmc: PMC7963237
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2274-2279Informations de copyright
© 2020 by American Journal of Neuroradiology.
Références
Soc Stud Sci. 2018 Dec;48(6):846-868
pubmed: 30230420
AJNR Am J Neuroradiol. 2013 Apr;34(4):730-4
pubmed: 23257609
J Neurointerv Surg. 2013 Sep 1;5(5):426-9
pubmed: 22833623
J Vasc Surg. 2018 Oct;68(4):1047-1053
pubmed: 29789214
Eur J Vasc Endovasc Surg. 2019 Feb;57(2):199-211
pubmed: 30414802
Front Neurol. 2018 Dec 13;9:1046
pubmed: 30619028
Skeletal Radiol. 2011 Aug;40(8):959-61
pubmed: 21667147
AJNR Am J Neuroradiol. 2020 Jul;41(7):1142-1148
pubmed: 32499251
J Neurointerv Surg. 2019 Jul;11(7):694-698
pubmed: 30552166
J Neurointerv Surg. 2020 Sep;12(9):862-868
pubmed: 32102920
J Neurointerv Surg. 2015 Mar;7(3):170-5
pubmed: 25387730
AJNR Am J Neuroradiol. 2015 Nov;36(11):2090-5
pubmed: 26251435
Lancet. 2012 Aug 25;380(9843):731-7
pubmed: 22748820
Eur J Vasc Endovasc Surg. 2018 Jan;55(1):3-81
pubmed: 28851594
AJNR Am J Neuroradiol. 2015 Dec;36(12):2340-5
pubmed: 26294652
Lancet Neurol. 2013 Jul;12(7):677-88
pubmed: 23726849